IGF1R inhibition has resulted in enhanced sensitivity to general cytotoxic and radiation‐based therapies in other cancers 67, 68, 69, and recent results for TGCT cell lines show positive but mixed results for cisplatin combined with mTOR, EGFR, and IGF1R inhibitors 59. This evidence concerns the gene EGFR and cancer.